Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert B Diasio, Tae Won Kim, Ron H. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku, Markus Joerger

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Beumer, J. H., Chu, E., Allegra, C., Tanigawara, Y., Milano, G., Diasio, R. B., Kim, T. W., Mathijssen, R. H., Zhang, L., Arnold, D., Muneoka, K., Boku, N., & Joerger, M. (Accepted/In press). Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1124